Nasdaq ardx.

Principal Financial Group Inc. acquired a new stake in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 24,269 shares of the biopharmaceutical company’s stock, valued at approximately $82,000. …WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...How much is Ardelyx stock worth today? ( NASDAQ: ARDX) Ardelyx currently has 232,137,709 outstanding shares. With Ardelyx stock trading at $4.33 per share, the total value of Ardelyx stock (market capitalization) is $1.01B. Ardelyx stock was originally listed at a price of $14.11 in Jun 19, 2014.Nasdaq -32.27(-0.23%) Russell 2000 1,809.02 +5.21(+0.29%) Crude Oil 75.61 -2.25(-2.89%) Gold 2,056.10 -11.00(-0.53%) Advertisement Ardelyx, Inc. (ARDX) NasdaqGM - NasdaqGM Real Time Price....

A total of 14 hedge funds in Insider Monkey’s database of hedge funds had stakes in Ardelyx Inc. (NASDAQ:ARDX). The most significant stake in Ardelyx Inc. (NASDAQ:ARDX) was owned by. 6.

Shares of Ardelyx, Inc. (NASDAQ:ARDX) got a boost, shooting 37% to $1.6750 after the company announced the FDA Advisory Committee voted 9-to-4 that the benefits of XPHOZAH outweigh its risks for ...

According to Seeking Alpha data, Ardelyx's market cap of $864.92M shows decent market confidence, especially with its robust revenue growth forecasts: 2023 at …Join the Nasdaq+ community for more personalized data, exclusive content, and market analysis. Try it today for $4.99/month. Subscribe Now.ARDELYX INC ( ARDX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

The US FDA has accepted an NDA resubmission from Ardelyx ( NASDAQ: ARDX) for Xphozah (tenapanor) as a chronic kidney disease treatment. The agency determined the application is subject a a class 2 ...

Find the latest dividend history for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.

Dec 1, 2023 · Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Ardelyx has an average ... 13.89. 970.71 · Barron's 400. 21.63. 1009.51 · Market Data; /; Stocks; /; ARDX; /; Financials. Ardelyx Inc. U.S.: Nasdaq. Watchlist. after hours. $ 4.9400. ARDX.AAPL. 189.69. -0.01%. 49.41M. View today's Ardelyx Inc stock price and latest ARDX news and analysis. Create real-time notifications to follow any changes in the live stock price.Nov 20, 2023 · Ulysses Erickson. November 20, 2023. In the latest trading session, 1.04 million Ardelyx Inc (NASDAQ:ARDX) shares changed hands as the company’s beta touched 1.03. With the company’s most recent per share price at $4.30 changed hands at -$0.03 or -0.69% at last look, the market valuation stands at $998.20M. ARDX’s current price is a ... Ardelyx, Inc. (NASDAQ:ARDX) has gained about 353% over the past 12 months. As of the end of the first quarter of 2023, 20 hedge funds tracked by Insider Monkey were long Ardelyx, Inc. (NASDAQ:ARDX ...

In the latest trading session, Ardelyx (ARDX) closed at $3.02, marking a -1.63% move from the previous day. This change lagged the S&P 500's 0.28% gain on the day. At the same time, the Dow added ...Dec 29, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs. A high-level overview of Ardelyx, Inc. (ARDX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Citigroup Inc. decreased its position in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 49.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the ...Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...On March 3, 2023, Wedbush upgraded their outlook for Ardelyx (NASDAQ:ARDX) from Neutral to Outperform.. Analyst Price Forecast Suggests 47.30% Upside. As of March 4, 2023, the average one-year ...

Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor for adult patients with CKD on dialysis with hyperphosphatemia. The company will host a conference call on December 29, 2022, at 8:00 AM ET. To participate in the conference call, please call (866) 374-5140 (toll-free) or (404) 400-0571 (toll) and …

Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript October 31, 2023 Ardelyx, Inc. beats earnings expectations. Reported EPS is $0.02909, expectations were $-0.11. Operator: Good day and ...Source. Headline. Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference. finance.yahoo.com - November 21 at 8:22 AM. Insider Selling: Ardelyx, Inc. (NASDAQ:ARDX) Insider Sells $100,000.00 in Stock. americanbankingnews.com - November 20 at 5:34 AM. Ardelyx, Inc.: XPHOZAH …Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, surging 15% in the last week alone Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ...13 thg 9, 2023 ... Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation.Nov 6, 2023 · WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ... Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ...Get Ardelyx Inc (ARDX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...

Mar 6, 2023 · On March 02, Ardelyx ( NASDAQ: ARDX ), now nearly a $800 million cap biopharmaceutical company reported 2022 financial results and provided a business update. Since the initial coverage, shares ...

Ardelyx, Inc. (NASDAQ:ARDX) Number of Hedge Fund Holders: 16 Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company that designs and sells treatments for gastrointestinal, heart, and kidney ...Factors of Influence in 2019, Key Indicators and Opportunity within Cousins Properties, Versum Materials, Meritor, Ardelyx, Molecular Templates, and Talend S.A — New Research Emphasizes Economic ...Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts.The analysts have sharply increased their revenue ...AAPL. 189.69. -0.01%. 49.41M. View today's Ardelyx Inc stock price and latest ARDX news and analysis. Create real-time notifications to follow any changes in the live stock price.Ardelyx Inc (NASDAQ:ARDX) trade information. Instantly ARDX has showed a red trend with a performance of -1.60% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.49 on Monday, 11/27/23 increased the stock’s daily price by 4.01%.Find the latest Insider Activity data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...

Ardelyx (NASDAQ:ARDX) is a biopharmaceutical innovator specializing in renal and cardiovascular care, driving novel therapeutic solutions forward.The stock has consistently shown a positive ...The forecasts range from a low of 6.06 to a high of $12.60. The average price target represents an increase of 81.50% from its latest reported closing price of 4.73. leaderboard of companies with ...WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Instagram:https://instagram. api oil inventory reportpdt rule optionsmandt refinance rateshigh risk high reward stocks Find the latest on short interest for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Ardelyx Inc. ARDX Ardelyx has made significant strides with its launch of Ibsrela for irritable bowel syndrome in the U.S. and the subsequent Food and Drug Administration (FDA) approval of Xphozah ... magic weight loss pillasp cadaver bag Ardelyx, Inc. Common Stock (ARDX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. nasdaq bank index Dec 18, 2022 · Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ... Nov 29, 2023 · See the latest Ardelyx Inc stock price (ARDX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Ardelyx Inc. ARDX Ardelyx has made significant strides with its launch of Ibsrela for irritable bowel syndrome in the U.S. and the subsequent Food and Drug Administration (FDA) approval of Xphozah ...